arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

CYANOTECH CORP

CYAN
Price unavailable
Materials ·Medicinal Chemicals & Botanical Products ·USMedicinal Chemicals & Botanical Products
17 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
26
Health
Poor
Bearish
auto_awesome

Analytical Summary

CYANOTECH CORP faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth 5.0%
Op. Margin -10.4%
ROIC -18.5%
FCF / Share $-0.17
Trailing P/E
Price / Book
FCF Yield
Debt / Equity 0.62
info Valuation on last close.

17-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$24.21M
↑ +5.0%
Net Income Profit after all expenses
$-3.20M
↑ +39.2%
Operating Margin Operating profit as % of sales
-10.4%
↑ +48.0% 15th
FCF / Share Free cash flow per share
$-0.17
↓ -143.7%
Long-Term Debt Long-term obligations
$4.71M
↓ -13.7%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
15
Returns
20
Financial Health
41
Cash Quality
35

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 17 years · 64 quarters